StockNews.AI
TLPH
StockNews.AI
146 days

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

1. Talphera will release Q4 and full-year 2024 financial results on March 31, 2025. 2. A conference call will discuss results and business updates for investors. 3. Talphera's lead product, Niyad™, is under FDA's Breakthrough Device Designation. 4. Niyad™ is being studied as an anticoagulant for the extracorporeal circuit. 5. Investors can join the webcast or call for insights into financial performance.

Earnings
-3.11%Current Return
VS
-0.27%S&P 500
$0.639903/26 04:49 PM EDTEvent Start
$0.6203/27 11:34 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and strategic insights can attract investor interest, supporting price.

How important is it?

The announcement of earnings dates and product recognition can influence stock performance significantly.

Why Short Term?

The financial results announcement may lead to immediate market reactions from investors.

Related Companies

TLPH
, /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event. Conference Call Information Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 11814. About Talphera, Inc. Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA). This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com. SOURCE Talphera, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News